Sclerotic fibroma (storiform collagenoma)-like stroma in a fibroadenoma of axillary accessory breast tissue.

Anatomical Pathology Department, Marqués de Valdecilla, University Hospital, Medical Faculty, University of Cantabria and IFIMAV, Santander, Spain.
Journal of Cutaneous Pathology (Impact Factor: 1.56). 07/2012; 39(8):798-802. DOI: 10.1111/j.1600-0560.2012.01940.x
Source: PubMed

ABSTRACT Accessory breast tissue is a subcutaneous remnant persisting after normal embryological development of the breast. It occurs most frequently in the axilla. Fibroadenomas in axillary breast tissue are rare. We report the case of a 29-year-old female patient who presented a fibroadenoma arising in the accessory breast tissue of the right axillary fossa. The neoplasm showed foci of sclerotic fibroma-like stroma. The patient had no signs of Cowden's syndrome. To the best of our knowledge, a lesion of this kind has not been previously reported. This stromal change suggests an uncommon involutional phase of the fibroadenoma with production of sclerotic and hypocellular collagen. The lesion should be differentiated from extraneural perineuroma, from the changes in fibroadenomas in Cowden's syndrome, from sclerosing lobular hyperplasia (fibroadenomatoid mastopathy) and from pseudoangiomatous stromal hyperplasia.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Smooth muscle actin (SMA) positive myofibroblasts have been implicated in tumour invasion; however, acquisition of SMA is not limited to peritumorous fibroblasts and other changes in fibroblasts may be more specifically related to the malignant environment. CD34 is a sialomucin expressed by normal breast fibroblasts but lost in invasive carcinomas. The aim of this study was to establish the relation between CD34 and SMA expression in breast fibroblasts and to analyse whether loss of CD34 is specific for invasive disease. Immunohistochemistry for CD34 and SMA was performed on 135 cases including 10 normal, 10 fibroadenomas, 40 infiltrating ductal carcinomas, 55 cases of ductal carcinoma in situ (DCIS), and 20 radial scar/complex sclerosing lesions. The relation between staining pattern and histopathological features was recorded as positive, negative, or reduced. Fibroblasts around all normal duct-lobule units and those showing epithelial hyperplasia were CD34 positive and mainly SMA negative. In fibroadenomas, fibroblasts retained CD34 but acquired SMA expression. In contrast, fibroblasts around invasive carcinoma were CD34 positive and SMA negative. In DCIS, loss of CD34 was significantly more frequent in high grade tumours than in low or intermediate grade ones (p < 0.001). The acquisition of SMA was seen more frequently than the loss of CD34, particularly in non-high grade DCIS. In all radial scars, fibroblasts were SMA positive but CD34 negative, and a similar pattern was seen in stromal cells in areas of fibrosis following core biopsy. These results show that SMA positive myofibroblasts exhibit variable expression of CD34, indicating that these markers are not coordinately controlled. Loss of CD34 is strongly related to the malignant phenotype, in both invasive and preinvasive disease, but is not entirely specific because radial scar fibroblasts and fibroblasts in reactive fibrosis exhibit a similar phenotype. The functional relevance of altered CD34 expression is unclear but the very focal changes implicate local signalling mechanisms probably of epithelial origin.
    Journal of Clinical Pathology 04/2003; 56(4):271-6. · 2.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sixty-nine cases of axillary accessory breast tissue, including its physiologic changes and pathologic lesions, were diagnosed by fine needle aspiration cytology. The age of the patients ranged from 13 to 40 years, with a median of 25, and all were female. The cases presented with swellings in the left axilla in 16 cases, right axilla in 30 cases and both axillae in 23 cases. The common clinical diagnoses included accessory breast tissue (23.2%), lipomatous lesion (17.4%), lymphadenopathy (18.8%) and swellings not otherwise specified (30.4%). In 8.8% cases two of the possibilities were considered. The cytodiagnoses included axillary accessory breast tissue (47 cases), axillary breast tissue with pregnancy or lactational changes (15), cystic disease (4) and fibroadenoma (3). One of the cystic disease cases showed granulomatous inflammation. Although no case of carcinoma in axillary breast tissue was diagnosed during the study period, there were two cases of malignancy in axillary swellings (diagnosed as metastatic carcinoma) when no primary was detected in the breasts.
    Acta cytologica 01/1994; 38(2):130-5. · 1.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sclerotic fibroma was first described in association with Cowden's disease by Weary et al. in 1972. In 1989, Rapini and Golitz detailed 11 cases of solitary sclerotic fibroma (SFS) in the absence of Cowden's disease, suggesting the term SFS of the skin. Classic histological features include hypocellular, hyalinized bands of collagen sharply demarcated from the surrounding skin. Numerous authors have described sclerotic fibroma-like changes in other entities including melanocytic nevi, dermatofibromas, lipomas, tendon sheath fibromas, giant cell collagenomas, neurofibromas, angiofibromas, erythema elevatum diutinum, and folliculitis. Dissension has arisen, with some dermatopathologists asserting that sclerotic fibroma is just an evolutionary end-point of a previous lesion. Others contend that SFS is a distinct lesion and cite recurrent cases and/or proliferation marker studies to corroborate this view. We detail the histopathological findings of lesions consistent with the classic description of SFS and compare these to sclerotic changes observed in an intradermal nevus, blue nevus, erythema elevatum diutinum, neurofollicular hamartoma, angiofibroma, neurofibroma, accessory nipple, and dermatofibromas. Sclerotic fibroma-like change may be seen in a variety of lesions and may represent a common reaction pattern in the skin.
    Journal of Cutaneous Pathology 06/2004; 31(5):373-8. · 1.56 Impact Factor